arrow
P

Peter D. Cole

Rutgers University
H指数:38
被引数:4,324

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

2026年ASH指南:青少年和年轻成人急性淋巴细胞白血病复发/难治性疾病的诊疗管理

2026-07-040
OA
Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity

铜耗竭通过线粒体复合物IV活性受损抑制核苷酸合成来促进中枢神经系统白血病治疗

2026-05-250
PRE
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

伊匹木单抗、纳武利尤单抗和 Brentuximab Vedotin 治疗复发霍奇金淋巴瘤的随机二期研究

Blood
IF23.1
2026-04-011
PRE
Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001

急性淋巴细胞白血病(ALL)患儿神经认知功能轨迹:Dana-Farber癌症研究所ALL联盟研究16-001

2026-01-010
PRE
CSF metabolomic signature during therapy for childhood acute lymphoblastic leukemia predicts subsequent working memory impairment

儿童急性淋巴细胞白血病治疗期间脑脊液代谢组学特征可预测后续工作记忆障碍

2025-12-300
OAAI
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults

儿童、青少年和年轻成人复发霍奇金淋巴瘤的无移植治疗方法

2025-01-022
PRE
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment
2024-09-090
OAAI
Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized children's oncology group phase 3 trial (AHOD1331)
2023-04-041
PRE